A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants
who completed the EXCELS study (NCT00252135) and had received long-term treatment with
Xolair. In addition, participants who did not participate in the EXCELS study but received
long-term (~5 years) treatment with Xolair were allowed to enter the study.